Navigation Links
Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
Date:12/15/2008

BRIDGEWATER, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S., an affiliate of sanofi-aventis, one of the world's leading pharmaceutical companies, announced today that starting January 1, 2009, it has increased access to its non-oncology Patient Assistance Programs (PAP)s to include eligible uninsured patients with incomes up to 250% of the Federal Poverty Level.

These PAPs assist patients with limited financial resources in gaining access to needed sanofi-aventis U.S. prescription medicines by focusing on individual patients and acting as a resource for those patients and their advocates. Uninsured individuals with income levels of up to $26,000 and uninsured families of four with combined income of up to $53,000 may be eligible to receive sanofi-aventis U.S. prescription drugs at no charge through the expanded U.S. Traditional PAP.*

"Sanofi-aventis U.S. remains committed to making our prescription medicines available to uninsured and low income patients through our PAPs," stated Greg Irace, President and CEO of sanofi-aventis U.S. "We have taken several steps to help patients with the greatest financial need access these medications."

The sanofi-aventis U.S. Patient Assistance Programs include medicines for many different disease states, including: Diabetes, Rheumatoid Arthritis, Urology, Dermatology, Blood Clotting (Deep Vein Thrombosis, Pulmonary Embolism), and Allergies. For more information, please contact the sanofi-aventis U.S. Traditional PAP at 1-800-221-4025.

PACT+(R) (Providing Access to Cancer Therapy), is Sanofi-aventis U.S.'s PAP for Cancer medications. PACT+ provides access to our oncology brands for eligible low income patients with an income of no greater than 500 percent of the Federal Poverty Level. PACT+ also provides reimbursement support services plus offers help in identifying a variety of alternative services and resources to support the specific needs of cancer patients. For more information on PACT+, please call 1-800-996-6626.

In addition, sanofi-aventis U.S. is a proud participant in The Partnership for Prescription Assistance which brings together America's pharmaceutical companies, doctors, other health care providers, patient advocacy organizations and community groups to help qualifying patients who lack prescription coverage get the medicines they need through the public or private program that's right for them. Call 1-888-477-2669 or visit www.pparx.org.

*Federal Poverty Limits change annually and are issued by the US Department of Health and Human Services.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, visit: www.sanofi-aventis.us or www.sanofi-aventis.com

Contact: Marc Greene, sanofi-aventis, 212-551-4780


'/>"/>
SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
2. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
3. Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1):
4. Sanofi-aventis Teams With HHS Quality Agency to Distribute Consumer Health Materials
5. Sanofi-aventis Named One of Best Employers for Healthy Lifestyles by National Business Group on Health
6. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
7. TechTeam Global Will Provide Multilingual EDC Support Services for sanofi-aventis recherche & developpement
8. Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
9. Sanofi-aventis Announces a Good Third Quarter Performance; Increase in 2007 full-year earnings growth guidance
10. Sanofi-aventis US Chairman Tim Rothwell Addresses CMSAs Collaborative Practice Summit
11. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, ... relay – Miles by Moonlight to raise money for the American Heart Association Heart ... , Teams will work together to keep their treadmills moving for 5 hours. ...
(Date:10/12/2017)... ... 12, 2017 , ... Health Literacy Innovations (HLI), creator of ... and the Cancer Patient Education Network (CPEN), an independent professional organization that shares ... strategic alliance. , As CPEN’s strategic partner, HLI will help support CPEN ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer Dr. ... colleagues, skilled nursing facility medical directors and other clinicians at various events in ... , "At many of these conferences we get to educate other physicians, facility ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vodori, ... Flow promotional review platform at the Promotional Review Committee Compliance and Best ... marketers streamline the medical, legal, and regulatory review (MLR) process – which ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
Breaking Medicine Technology: